Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential 'First Strike, Second Strike' Therapies in HR+ Metastatic Breast Cancer
NCT06409390Phase 2Recruiting
- Sponsor
- Moffitt Cancer Center
- Start
- Aug 2024
- Primary completion
- Apr 2027
- Modality
- Monoclonal Antibodies, DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of docetaxel, cyclophosphamide, trastuzumab deruxtecan, sacituzumab govitecan, capecitabine in Hormone-Receptor-Positive Breast Cancer, sponsored by Moffitt Cancer Center. Started Aug 2024; status: recruiting.
02
Drugs
docetaxelcyclophosphamidetrastuzumab deruxtecansacituzumab govitecancapecitabine
03
Conditions
Hormone-Receptor-Positive Breast Cancer
Beyond the preview
Go deeper on NCT06409390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06409390.